annual total cost per subject in relation to disease severity (GOLD) was: €783 (mild), €2,567 (moderate), €6,818 (severe), and €19,927 (very severe). Indirect costs were higher than direct costs in all severity stages. For direct costs, main cost drivers were hospitalizations in severe and very severe disease, and drugs in mild and moderate COPD, respectively. The main cost driver in indirect costs was productivity loss due to early retirement, except in mild disease where the driver was sick-leave. In comparison with a similar study performed in 1999 a numerical increase in mean annual total costs per subject was observed (ns). The total costs of COPD in 2010 could be estimated to about €1212-1469 million, with indirect costs accounting for about 70% of the total costs. CONCLUSIONS: The costs of COPD are still high in Sweden, and the costs increase considerably by disease severity. belonging to Badalona (population Ն 18 years: 90,315) and attended by 6 primary care centres and 2 hospitals (68,274 patients seen throughout the study period, 6 months). Economical analysis (resource utilization and direct/ indirect associated cost) is presented. Statistical analysis was performed through a regression model and Bonferoni-adjusted ANCOVA; pϽ0.05. RESULTS: Among the 581 patients identified [55.6% males, mean age 57.5 (SD 19,1)], 41.5% (241) were hospitalized. Total cost per patient was 1365.97€ (85.2% related to health care direct costs and 14.8% to non-health care costs due to sick leaves). Ambulatory care accounted for 154.24€ (13.25%) and hospital care 1010.25€ (86.75%) of the direct costs; pϽ0.001. Greater impact was due to hospitalization length of stay (71.47%), primary care pharmacological costs (13.24%) and specialist visits (11.42%). CAP costs were related to age (rϭ0.303); Fine scale score (rϭ0.437) and re-hospitalization (rϭ0.667); pϽ0.001. Overall cost per patient increased with age (1138€ in patients Ͻ 65 year-old vs. 1716€ in Ն 65 year-old; pϽ0.001). CONCLUSIONS: CAP is still associated with high economic burden in our country which is mainly due to hospital care cost (almost one out of two patients were hospitalized). New preventive measures under development could reduce this impact.
PRS22 ESTIMATION OF DIRECT AND INDERCT COSTS OF COPD IN UKRAINE: THE PILOT STUDY RESULTS
Tolubaiev V 1 , Zalis'ka O 1 , Ostrovskyy M 2 , Korzh G 2 , Yakovenko O 3 , Holovatyuk I 4 1 Danylo Halytsky Lviv National Medical University, Lviv, Ukraine, Ukraine, 3 Volyn Regional Clinical Hospital, Lutsk, Ukraine, 4 O. O. Bohomolets National Medical University, Kyiv, Ukraine OBJECTIVES: The first official data on COPD prevalence, morbidity and mortality in Ukraine were introduced in 2009 report of National Center of Medical Statistics (2010) . Nevertheless, there were no information on a number of specialists' consultations, a number of disability days and hospitalizations' frequency in Ukrainian COPD patient cohort. METHODS: Real-life 12 previous month's data from the personal medical cards (90%) and interview-lists (10%) of II-III severity stage COPD patients were analyzed retrospectively. The study was conducted in three regional clinical centers Bila-Tserkva (Kiev region), Ivano-Frankivsk, Lutsk (Volyn' region). Costs of COPD were calculated through the analysis of a number of GPs' and pulmonologists' consultations, a number of lost working days due to COPD, and COPD related hospitalizations frequency during the last 12 months. Direct medical costs included outpatient costs (specialists' consultations, control spirometry once a year) and inpatient costs (diagnostic measures and hospital-service costs), indirect costs included productivity loss (absenteeism and presenteeism) and disability compensations. The 2010-2011 medical service inflation (11.45%), salary growth rate (25%), social tax (18.6%) and Value Added Tax (17%) discounted the calculations. Exchange rate: 1EUR ϭ 11.42UAH on 18.06.2011. RESULTS: The total study sample contained 132 patients, aged from 24 to 65 (mean age 49.49Ϯ10.02), males -60.61 %. The number of GPs' and Pulmonologists' consultations per COPD patient was 2.63 and 1.18 per year respectively. The number of lost working days due to COPD was 12.63 per patient annually and a frequency of COPD related hospitalizations was 0.56 per 12 months. The total COPD costs in Ukraine in 2009 were €38870506 (103.03 per patient) with €28448213 (73.8%) direct medical costs and €10422293 (26.82%) indirect costs. CONCLUSIONS: The pilot study results showed that costs per COPD patient in Ukraine are large and could correspond with costs in several EU countries. Nevertheless, COPD in Ukraine is underdiagnosed and underestimated.
PRS23 HIGH COST CYSTIC FIBROSIS PATIENTS AS IDENTIFIED IN A US CLAIMS DATABASE: A CLOSER LOOK AT THE TAIL
Harrow B 1 , Becker CC 1 , Buikema A 2 1 Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA, 2 OptumInsight, Eden Prarie, MN, USA OBJECTIVES: Cystic fibrosis (CF) is an inherited disease that leads to progressive damage to the respiratory system, the digestive system, and other organs. Medical care utilization for patients with CF can be substantial. Recent studies of privately insured patients with CF in the US have been fairly consistent in their estimates of annual costs for the average or median patient with CF. However, the variation in cost is considerable and those patients in the tail of the distribution are also those with the most severe disease. METHODS: A national employer based claims database for the years 2004 to 2008 was used to identify patients with a valid CF diagnosis using multiple criteria. There were a total of 5019 unique patients with CF who had at least 1 year of continuous enrollment in the health plan. Annual all cause costs were calculated in total and by different settings and type of cost. The distribution of total costs was examined and the top 2.5 percentile (111 patients) were identified as high cost users. RESULTS: While the average annual cost was approximately $50,000 for patients in our data, the average for the high cost users was over tenfold higher and ranged between $270,000 and $3.1 million. The vast majority of these costs were for inpatient stays with the average number of days spent in the hospital of 87 days. CONCLUSIONS: In this study we used a US administrative claims database to take a closer look at the most resource intensive patients with CF. A greater understanding of this group can help inform stakeholders of the level of expenses to be incurred in the treatment of severe illness and aid in cost-analysis of treatments.
PRS24

IMPACT OF AGE AND PATIENT CO-MORBIDITIES ON COMMUNITY ACQUIRED PNEUMONIA (CAP) RELATED COSTS AT THE HOSPITAL SETTING IN A WELL DEFINED AREA OF BARCELONA (BADALONA, SPAIN)
Sicras-Mainar A 1 , Guijarro P 2 , de Salas-Cansado M 2 , Cifuentes-Otero I 2 , Navarro-Artieda R 3 1 Directorate of Planning, Badalona Serveis Assistencials, Badalona, Barcelona, Spain, 2 Pfizer Spain, Alcobendas, Madrid, Spain, 3 Hospital Universitari Germans Trias i Pujol, Barcelona, Spain OBJECTIVES: This study aimed to assess the economical impact of the hospitalized CAP patients identified through the study period. METHODS: Retrospective review of medical records of all patients Ն18 years old diagnosed with CAP from January 1, 2008 to December 31, 2009 belonging to Badalona (population Ն 18 years: 90,315) and attended by 6 primary care centres and 2 hospitals (68,274 patients seen throughout the study period). Economical analysis of hospitalized CAP (resource utilization and direct/indirect associated cost) is presented. Statistical analysis was performed through a regression model and Bonferoni-adjusted ANCOVA; pϽ0.05. RESULTS: Among the 518 patients diagnosed with CAP included, 241 were hospitalized (41.5%), mean age 66.6 (SD 16.4) years-old, 55.6% males. Adjusted mean total cost per patient was 2,332.4€ (sick leaves: 191.6€ and health care costs: 2,140.8€). Healthcare cost was mainly caused by hospital length of stay and specialist visits costs. Likelihood of inpatient admission increased with liver disease (ORϭ5.9), stroke (ORϭ3.6), dementia (ORϭ3.5), COPD (ORϭ2.9), diabetes mellitus (ORϭ1.9) and age (ORϭ 1.1); pϽ0.002. Patient suffering from these co-morbidities (except dementia) had higher hospital related costs: liver disease (2896.6€); stroke (2960.2€), COPD (2701.9€) and diabetes mellitus (3,057.7€); pϽ0.001. Direct hospital costs per patient increased with patient age (805€ in patients Ͻ 65 year-old vs. 1,716€ in Ն 65 year-old; pϽ0.001). Streptococcus pneumoniae was the most prevalent pathogen identified [82/114 culture-positive inpatients (71.9%)]. Patients with confirmed pneumococcal pneumonia had greater overall mean cost (2864.7€ vs. 2259.8€; pϭ0.041) and healthcare cost (2722.1€ vs. 2,153.6€; pϭ0.047) than those not-confirmed. CONCLUSIONS: CAP caused great hospital resource utilization, mainly due to hospitalization days. Those patients older and/or suffering from co-morbidities had greater likelihood for inpatient admission and higher hospital related costs. 
PRS25 SYSTEMATIC LITERATURE REVIEW OF ECONOMIC AND HUMANISTIC BURDEN OF DYSPNOEA IN COPD
OBJECTIVES:
To review published evidence on the economic and humanistic (health related quality of life (HRQoL)) burden of dyspnoea in patients with chronic obstructive pulmonary disease (COPD). METHODS: A systematic literature search was performed using PubMed and Embase databases. Search terms identified studies on economic and humanistic burden of dyspnoea in patients with COPD published since 2000 in English. RESULTS: Two articles for economic burden and six for humanistic burden were identified. The economic studies used different methodology; one a cohort study and another chart review. Both studies showed that dyspnoea within COPD is associated with higher costs. Five quantitative and one qualitative study were identified for humanistic burden. The quantitative studies concluded there is a correlation between dyspnoea and QoL. Although considerable variation was observed around the parameters used to define dyspnoea, including forced expiratory volume in one second (FEV 1 ) forced vital capacity (FVC), baseline dyspnoea index (BDI) and transitional dyspnoea index (TDI) and instruments used to assess QoL, including the World Health Organisation quality of life -BREF (WHOQOL-BREF), Borg scale and chronic respiratory disease questionnaire (CRQ). The qualitative study was based on interviews. Patients identified breathlessness as the worst COPD symptom, affecting nutritional intake and an association with anxiety. Overall, humanistic burden studies showed dyspnoea has a significant impact on the QoL. The main limitations of the reviewed studies were variation in instruments used to assess QoL and dyspnoea and small sample size (range: nϭ10-nϭ130). CONCLUSIONS: Studies identified in this review varied in methodological approach and were based on relatively small patient populations. The findings of this review suggest dyspnoea may be an important predictor of health related quality of life and economic burden in COPD. There are significant limitations in the current evidence base, further research is required before firmer conclusions can be drawn.
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